Historique
Article de Périodique
Patients admitted for inpatient cannabis detoxification: withdrawal symptoms and impacts of common comorbidities (2011)
Auteur(s) :
DAWES, G. M. ;
SITHARTHAN, T. ;
CONIGRAVE, K. M. ;
PHUNG, N. ;
WELTMAN, M.
Année
2011
Page(s) :
392-405
Langue(s) :
Anglais
Domaine :
Drogues illicites / Illicit drugs
Discipline :
PSY (Psychopathologie / Psychopathology)
Thésaurus mots-clés
DESINTOXICATION
;
CANNABIS
;
SEVRAGE
;
ETUDE CLINIQUE
;
COMORBIDITE
;
PSYCHOPATHOLOGIE
;
PRISE EN CHARGE
;
SYNDROME DE SEVRAGE
;
CURE DE DESINTOXICATION
Thésaurus géographique
AUSTRALIE
Résumé :
Introduction: There is clinical impetus to accurately monitor cannabis withdrawal symptoms. In doing this the impact of other drug and mental health comorbidities should be considered.
Aims: To report patient demographics, psychiatric and substance use comorbidities and symptoms of cannabis withdrawal in the first 5 days of hospital admission for detoxification.
Design: Daily self-reported symptom severity ratings were analysed as functions of gender, secondary drug use and recent mental health history.
Setting: Specialised inpatient hospital unit for withdrawal management (detoxification) at a University of Sydney teaching hospital, Sydney, Australia.
Participants: Total 193 consecutive patients admitted for routine inpatient cannabis withdrawal management over a 9-month period.
Measurements: Patients screened via daily self-reported subjective ratings of cannabis withdrawal.
Findings: Average cannabis used per day was 2.6 g. Most patients smoked tobacco daily (91%) and half of the sample (53%) reported other drug use. Alcohol was the main secondary drug used (29%). Half of the patients (51%) reported recent contact or interventions for mental health concerns. We were able to delineate principal withdrawal features to include "anxiety" (physical tension, hypermentation, palpitations and excessive worry), dysphoria (+ anergia, anhedonia, lethargy and somnolence) and irritability/agitation. Additional features identified included mood swings and cravings for cannabis. These features all significantly declined over a 5-day admission. Recent mental health concerns, but not gender or secondary drug use, correspond to greater global symptom severity over the course of admission.
Conclusions: This study underscores a need to be alert to the impacts of comorbidities that are common in this treatment-seeking population, especially secondary drug use and the potential for mental health issues which add dimensions of complexity.
Aims: To report patient demographics, psychiatric and substance use comorbidities and symptoms of cannabis withdrawal in the first 5 days of hospital admission for detoxification.
Design: Daily self-reported symptom severity ratings were analysed as functions of gender, secondary drug use and recent mental health history.
Setting: Specialised inpatient hospital unit for withdrawal management (detoxification) at a University of Sydney teaching hospital, Sydney, Australia.
Participants: Total 193 consecutive patients admitted for routine inpatient cannabis withdrawal management over a 9-month period.
Measurements: Patients screened via daily self-reported subjective ratings of cannabis withdrawal.
Findings: Average cannabis used per day was 2.6 g. Most patients smoked tobacco daily (91%) and half of the sample (53%) reported other drug use. Alcohol was the main secondary drug used (29%). Half of the patients (51%) reported recent contact or interventions for mental health concerns. We were able to delineate principal withdrawal features to include "anxiety" (physical tension, hypermentation, palpitations and excessive worry), dysphoria (+ anergia, anhedonia, lethargy and somnolence) and irritability/agitation. Additional features identified included mood swings and cravings for cannabis. These features all significantly declined over a 5-day admission. Recent mental health concerns, but not gender or secondary drug use, correspond to greater global symptom severity over the course of admission.
Conclusions: This study underscores a need to be alert to the impacts of comorbidities that are common in this treatment-seeking population, especially secondary drug use and the potential for mental health issues which add dimensions of complexity.
Affiliation :
Department of Addiction Medicine (Nepean, Westmead Hospitals), NSW Health, New South Wales, Sydney, Australia